Reslizumab (Cinqair)

Covered: Cinqair (reslizumab) is covered only as add‑on maintenance therapy for adults ≥18 with severe eosinophilic asthma (blood eosinophils ≥400 cells/µL) and off‑label/compendial uses are not covered. Key requirements: must be prescribed by/with an allergist, immunologist, or pulmonologist; documented ≥3 months of ICS plus another controller (or exception if on anti‑IL‑5 + ICS ≥3 months); evidence of uncontrolled asthma per exacerbation or spirometry criteria; dosing 3 mg/kg IV every 4 weeks; initial approval 6 months and reauthorization 12 months contingent on continued ICS and documented clinical benefit.

"Initial approval duration limited to 6 months."

Sign up to see full coverage criteria, indications, and limitations.